<< Back To Search

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
This trial is testing a new kind of imaging called [89Zr]DFO-YS5 positron emission tomography (PET) to see if it is safe and can detect a type of cancer called multiple myeloma. They are using a special substance called [89Zr]DFO-YS5 that has a tiny bit of radioactive material in it. This substance is injected into a vein to help doctors see different parts of the body. The [89Zr]DFO-YS5 targets a protein called CD46, which is found in certain cancer cells of multiple myeloma. The goal of this trial is to see if [89Zr]DFO-YS5 PET scans can be better at finding multiple myeloma.
*Third Opinion AI Generated Synopsis

Trial Summary
This phase I trial tests the safety of [89Zr]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. [89Zr]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body. [89Zr]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and [89Zr]DFO-YS5 PET scans may improve detection of multiple myeloma.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?